---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013391"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:30:10.445542+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "medium"
source: SEC EDGAR
---

# Oncotelic subsidiary Sapu Nano to present everolimus tissue-toxicity data at SOT 2026

## Summary
- Sapu Nano (Oncotelic minority interest) to present everolimus toxicology poster at SOT 2026 in San Diego on Mar 23.
- Presentation (#3539, board K692) focuses on tissue concentration-driven effects beyond traditional plasma pharmacokinetics.
- Data aims to inform improved delivery strategies for mTOR inhibitors, including IV and nanoparticle formulations.
- Oncotelic (OTLC) holds minority stake in Sapu Nano; no financial terms or guidance provided.

## SEC filing metadata
- accession: 0001493152-26-013391
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315226013391/0001493152-26-013391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315226013391/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013391
- JSON: https://secwatch.observer/filing/0001493152-26-013391.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013391.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.